Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia

Key facts

Sponsor

GOG Foundation

Principal Investigator

Julian C Schink, M.D

NRG Oncology

Intervention

Dactinomycin(biological)

Enrollment

57 enrolled

Eligibility

18 years · FEMALE

Timeline

2012 – 2020

Study locations (30)

• Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
• Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
• Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
• Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
• Alaska Regional Hospital, Anchorage, Alaska, United States
• Alaska Women's Cancer Care, Anchorage, Alaska, United States
• Anchorage Oncology Centre, Anchorage, Alaska, United States
• Katmai Oncology Group, Anchorage, Alaska, United States
• Providence Alaska Medical Center, Anchorage, Alaska, United States
• Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
• Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
• Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
• UC San Diego Moores Cancer Center, La Jolla, California, United States
• Loma Linda University Medical Center, Loma Linda, California, United States
• Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Gestational choriocarcinoma

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNANCT04562558
  Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia
  xiang yang

See all trials for Gestational choriocarcinoma →